For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
This is an Open Label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed an APL-2 study.
Active, not recruiting
Tue, 08/28/2018 to Sat, 08/20/2022
Bone Marrow Disease(s):
- paroxysmal nocturnal hemoglobinuria (PNH)
Experimental: 1,080 mg APL-2 administered subcutaneously 1,080mg APL-2 administered subcutaneously twice weekly or every three days. Drug: APL-2 Complement (C3) Inhibitor